Table 1 Cohort Characteristics (N = 58)
From: Metastatic breast cancer patient perceptions of somatic tumor genomic testing
| Â | N | % |
|---|---|---|
Age | ||
  < 45 | 7 | 12.1 |
 45–54 | 19 | 32.8 |
 55–64 | 17 | 29.3 |
  ≥ 65 | 15 | 25.9 |
Subtype | ||
 ER and/or PR+, HER2- | 35 | 61.4 |
 HER2+ | 3 | 5.3 |
 TNBC | 19 | 33.3 |
Race | ||
 Non-whitea | 11 | 19.0 |
 White | 47 | 81.0 |
Education | ||
 High school diploma/GED or lower | 17 | 29.3 |
 Some college, technical school, or Associate’s degree | 20 | 34.5 |
 Bachelor’s degree or higher | 21 | 36.2 |
Income | ||
  < $40,000 | 10 | 21.7 |
 $40,000–$69,999 | 9 | 19.6 |
 $70,000 or more | 27 | 58.7 |
Insurance type | ||
 Medicaid or Medicare | 12 | 21.4 |
 Private | 41 | 73.2 |
 Other | 3 | 5.4 |
Treatment change based on FM test | ||
 No | 41 | 87.2 |
 Yes | 6 | 12.8 |
Number of prior therapies in metastatic setting | ||
 Median (range) | 1 | (0,11) |